These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16451058)

  • 21. Interaction of phosphonate analogues of the tetrahedral reaction intermediate with 5-enolpyruvylshikimate-3-phosphate synthase in atomic detail.
    Priestman MA; Healy ML; Becker A; Alberg DG; Bartlett PA; Lushington GH; Schönbrunn E
    Biochemistry; 2005 Mar; 44(9):3241-8. PubMed ID: 15736934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).
    Attolino E; Calderone V; Dragoni E; Fragai M; Richichi B; Luchinat C; Nativi C
    Eur J Med Chem; 2010 Dec; 45(12):5919-25. PubMed ID: 20965620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
    Ghosh AK; Kumaragurubaran N; Hong L; Kulkarni SS; Xu X; Chang W; Weerasena V; Turner R; Koelsch G; Bilcer G; Tang J
    J Med Chem; 2007 May; 50(10):2399-407. PubMed ID: 17432843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties.
    Kawai M; BaMaung NY; Fidanze SD; Erickson SA; Tedrow JS; Sanders WJ; Vasudevan A; Park C; Hutchins C; Comess KM; Kalvin D; Wang J; Zhang Q; Lou P; Tucker-Garcia L; Bouska J; Bell RL; Lesniewski R; Henkin J; Sheppard GS
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3574-7. PubMed ID: 16632353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel multisubstrate inhibitors of mammalian purine nucleoside phosphorylase.
    Toms AV; Wang W; Li Y; Ganem B; Ealick SE
    Acta Crystallogr D Biol Crystallogr; 2005 Nov; 61(Pt 11):1449-58. PubMed ID: 16239721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
    Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors.
    Holmes CP; Li X; Pan Y; Xu C; Bhandari A; Moody CM; Miguel JA; Ferla SW; De Francisco MN; Frederick BT; Zhou S; Macher N; Jang L; Irvine JD; Grove JR
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4336-41. PubMed ID: 16046123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.
    Yang SM; Scannevin RH; Wang B; Burke SL; Huang Z; Karnachi P; Wilson LJ; Rhodes KJ; Lagu B; Murray WV
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1140-5. PubMed ID: 18083558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.
    Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K
    J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors.
    Puerta DT; Cohen SM
    Inorg Chem; 2003 Jun; 42(11):3423-30. PubMed ID: 12767177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insight into the structural determinants for selective inhibition of matrix metalloproteinases.
    Pirard B
    Drug Discov Today; 2007 Aug; 12(15-16):640-6. PubMed ID: 17706545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding of phosphinate and phosphonate inhibitors to aspartic proteases: a first-principles study.
    Vidossich P; Carloni P
    J Phys Chem B; 2006 Jan; 110(3):1437-42. PubMed ID: 16471695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
    Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
    J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.
    Behrends M; Wagner S; Kopka K; Schober O; Schäfers M; Kumbhar S; Waller M; Haufe G
    Bioorg Med Chem; 2015 Jul; 23(13):3809-18. PubMed ID: 25921268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups.
    Nicolotti O; Miscioscia TF; Leonetti F; Muncipinto G; Carotti A
    J Chem Inf Model; 2007; 47(6):2439-48. PubMed ID: 17958346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
    Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.
    Combs AP; Zhu W; Crawley ML; Glass B; Polam P; Sparks RB; Modi D; Takvorian A; McLaughlin E; Yue EW; Wasserman Z; Bower M; Wei M; Rupar M; Ala PJ; Reid BM; Ellis D; Gonneville L; Emm T; Taylor N; Yeleswaram S; Li Y; Wynn R; Burn TC; Hollis G; Liu PC; Metcalf B
    J Med Chem; 2006 Jun; 49(13):3774-89. PubMed ID: 16789735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent, selective pyrone-based inhibitors of stromelysin-1.
    Puerta DT; Mongan J; Tran BL; McCammon JA; Cohen SM
    J Am Chem Soc; 2005 Oct; 127(41):14148-9. PubMed ID: 16218585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rhodium carbene routes to oxazoles and thiazoles. Catalyst effects in the synthesis of oxazole and thiazole carboxylates, phosphonates, and sulfones.
    Shi B; Blake AJ; Lewis W; Campbell IB; Judkins BD; Moody CJ
    J Org Chem; 2010 Jan; 75(1):152-61. PubMed ID: 19954177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.